Uremia presented as acute cranial neuropathy

Hur, Wook; Chung, Ji Yeon; Choi, Pahn Kyu; Kang, Hyun Goo

doi:10.1007/s10072-019-03741-6

Cited by 3 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pain management is crucially challenging specifically for patients suffering from chronic pain like neuropathic pain (Khan et al, 2016). Moreover, chemotherapy-induced-neuropathy is one of the major adverse effects of anti-cancer drugs which halts the effectiveness of existing cancer chemotherapy (Hur et al, 2019;Vitet et al, 2018). Paclitaxel-induced neuropathy is a well-known adverse effect in humans and rodents.…”

Section: Discussionmentioning

confidence: 99%

Attenuation of nociceptive and paclitaxel-induced neuropathic pain by targeting inflammatory, CGRP and substance P signaling using 3-Hydroxyflavone

Ullah

Ali

Subhan

et al. 2021

Neurochemistry International

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Attenuation of nociceptive and paclitaxel-induced neuropathic pain by targeting inflammatory, CGRP and substance P signaling using 3-Hydroxyflavone

Ullah

Ali

Subhan

et al. 2021

Neurochemistry International

View full text Add to dashboard Cite

Attenuation of vincristine-induced neuropathy by synthetic cyclohexenone-functionalized derivative in mice model

Ali

Khan

et al. 2019

Neurol Sci

View full text Add to dashboard Cite

Diabetes and Metabolic Disorders and the Peripheral Nervous System

Gibbons¹

2020

CONTINUUM: Lifelong Learning in Neurology

View full text Add to dashboard Cite

PURPOSE OF REVIEW This article provides an up-to-date review of the manifestations of neuropathy seen in the setting of diabetes and other metabolic disorders. RECENT FINDINGS Although a number of metabolic disorders cause or are associated with peripheral neuropathy, the neuropathies associated with glucose dysregulation make up the vast majority of cases. Recent investigations have determined major differences in the neuropathies associated with type 1 and type 2 diabetes. Neuropathy in type 1 diabetes is closely linked to glycemic control, whereas neuropathy in type 2 diabetes is linked to dyslipidemia, central obesity, hypertension, insulin resistance, and glucose control. Although length-dependent axonal distal symmetric polyneuropathy is the most common clinical presentation, diabetes is also associated with acute, asymmetric, painless, and autonomic neuropathies. SUMMARY The prevalence of diabetes and metabolic syndrome is increasing across the globe. The need to recognize and treat the wide array of clinical manifestations of neuropathy detected in individuals with metabolic disorders will continue to grow. As a consequence, an increasing number of well-trained physicians who can manage these patients is needed. At present, treatment is largely focused on prevention and symptomatic management. Investments into funding for both basic and clinical science are necessary to bring novel therapeutic interventions into clinical practice.

show abstract

Uremia presented as acute cranial neuropathy

Cited by 3 publications

References 4 publications

Attenuation of nociceptive and paclitaxel-induced neuropathic pain by targeting inflammatory, CGRP and substance P signaling using 3-Hydroxyflavone

Attenuation of nociceptive and paclitaxel-induced neuropathic pain by targeting inflammatory, CGRP and substance P signaling using 3-Hydroxyflavone

Attenuation of vincristine-induced neuropathy by synthetic cyclohexenone-functionalized derivative in mice model

Diabetes and Metabolic Disorders and the Peripheral Nervous System

Contact Info

Product

Resources

About